Immunomedics Awarded 12 Qualifying Therapeutic Discovery Project Grants

MORRIS PLAINS, N.J., Nov. 2, 2010 (GLOBE NEWSWIRE) — Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of [...] http://bit.ly/cSSrAG